Log In Sign up
The largest database of trusted experimental protocols

Xenogen ivis system

Manufactured by PerkinElmer
Visit Supplier
Sourced in United States

The Xenogen IVIS system is an in vivo imaging platform that allows for the non-invasive visualization and quantification of bioluminescent and fluorescent reporters in small animal models. The system utilizes a sensitive charge-coupled device (CCD) camera to detect and record light emitted from luciferase or fluorescent protein-expressing cells or tissues within living animals.

Automatically generated - may contain errors

Lab products found in correlation

Hank s balanced salt solution, by Thermo Fisher Scientific (2 mentions) C57bl 6j mice, by Jackson ImmunoResearch (2 mentions) Dppiv glo protease assay, by Promega (2 mentions) Gly pro aminoluciferin, by Promega (2 mentions) Protease inhibitor cocktail, by Roche (2 mentions) Matrigel, by Corning (2 mentions) Living image software, by PerkinElmer (2 mentions) Living image acquisition and analysis software, by PerkinElmer (1 mentions) D luciferin, by PerkinElmer (1 mentions) Living image 3, by PerkinElmer (1 mentions) Luciferin substrate, by GoldBio (1 mentions) Nod scid il2rg mice, by Jackson ImmunoResearch (1 mentions) Matrigel, by BD (1 mentions) Nsg mice, by Jackson ImmunoResearch (1 mentions) Prism software, by GraphPad (1 mentions) Luciferin, by Thermo Fisher Scientific (1 mentions) Luciferin, by PerkinElmer (1 mentions) Nano glo luciferase assay substrate, by Promega (1 mentions)

Close spelling variants of this product

Xenogen IVIS Imaging System Xenogen IVIS Imaging system 200 series Xenogen IVIS Spectrum Imaging System Xenogen IVIS 200 in vivo fluorescence system Xenogen IVIS Spectrum system Xenogen IVIS Lumina system Xenogen IVIS-200 System Xenogen IVIS Lumina imaging system Xenogen IVIS® Spectrum In Vivo Imaging System Xenogen IVIS Spectrum Preclinical Imaging System

18 protocols using xenogen ivis system

1

Ovarian Tumor Induction in Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols
All animal work was done in accordance with a protocol approved by the Institutional Animal Care and Use Committee (IACUC) at the Medical College of Wisconsin. Female C57BL/6J mice were obtained from the Jackson Laboratory. Animals were cared for according to IACUC guidelines. All animals were 6 to 8 weeks of age at the time of injection. shRNA control and shRNA furin ID8 cells (1× 106 cells/animal) were prepared in Hanks’ balanced salt solution (Gibco, Carlsbad, CA) and injected into the ovarian bursa (10 mice/group). The mice were imaged once weekly for a bioluminescence signal, using a Xenogen IVIS system (PerkinElmer). At the time of necropsy, the weight, number, and distribution of tumors were recorded.
Chen C., Gupta P., Parashar D., Nair G.G., George J., Geethadevi A., Wang W., Tsaih S.W., Bradley W., Ramchandran R., Rader J.S., Chaluvally-Raghavan P, & Pradeep S. (2020). ERBB3-induced furin promotes the progression and metastasis of ovarian cancer via the IGF1R/STAT3 signaling axis. Oncogene, 39(14), 2921-2933.
+ Open protocol
+ Expand
2

Metastasis Tracking in Nude Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols
Animal experiments were performed according to the protocols approved by the Institutional Animal Care and Use Committee of Emory University. Nude mice (athymic nu/nu, female, 4–6-week old, Harlan, Indianapolis, IN, USA) were intravenously injected with 2.5 × 106 of A549-luc-GFP cells with RSK2 knockdown and expression of stathmin mutants. Metastasis was monitored by BLI analysis as described.37 (link) In brief, xenograft mice were administered 75 mg/kg of D-luciferin intraperitoneally 3 min before the BLI imaging (Perkin Elmer, Waltham, MA, USA, 15 mg/ml solution in sterile PBS). BLI images were acquired by using Xenogen IVIS system coupled to Living Image acquisition and analysis software (Perkin Elmer).
Alesi G., Jin L., Li D., Magliocca K., Kang Y., Chen Z., Shin D., Khuri F, & Kang S. (2016). RSK2 signals through stathmin to promote microtubule dynamics and tumor metastasis. Oncogene, 35(41), 5412-5421.
+ Open protocol
+ Expand
3

CAR-NK Cell Therapy for Leukemia

Check if the same lab product or an alternative is used in the 5 most similar protocols
Six-week-old immunodeficient NSG (NOD Scid gamma mouse) mice (Jackson Laboratories, Bar Harbor, ME, USA) were housed in accordance with the Institutional Animal Care and Use Committee (IACUC) (#LUM-001). Each mouse was subcutaneously injected on day 0 with 100 µL of 1 × 105 Nalm-6-luciferase positive cells. Human CAR-NK and NK cells generated by CAR mRNA transfection were frozen 24 h post-transfection. Frozen/thawed 5 × 106 NK or CAR-NK cells were intravenously injected to NSG mice on days 1, 3, 6, and 8. Imaging was performed on days 6, 9, 12, and 15 after luciferin injection using Xenogen Ivis System (Perkin Elmer, Waltham, MA, USA). Quantification of imaging was carried out by measuring bioluminescence (BLI) in photons/s signals.
Golubovskaya V., Sienkiewicz J., Sun J., Zhang S., Huang Y., Zhou H., Harto H., Xu S., Berahovich R, & Wu L. (2023). CAR-NK Cells Generated with mRNA-LNPs Kill Tumor Target Cells In Vitro and In Vivo. International Journal of Molecular Sciences, 24(17), 13364.
+ Open protocol
+ Expand
4

Evaluating Tumorigenicity and Bone Marrow Infiltration of Cancer Stem Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
In vivo experiments were done in accordance with the HMRI institutional guidelines for the use of laboratory animals. To determine tumorigenicity of regenerated SP cells, 8- to 10-week-old NOD/SCID IL2rg−/− mice (Jackson Laboratory, Bar Harbor, ME, USA) (six mice per group) were injected subcutaneously with 0.1 × 106 SP or NSP cell populations isolated from the RPMI8226 GL cell line and suspended in Matrigel (BD Biosciences). Tumor engraftment was monitored weekly by whole-body bioluminescence imaging. Luciferin substrate (Gold Bio Technology, St. Louis, MO, USA) was injected intraperitoneally (IP) and whole-body imaging performed on the Xenogen IVIS system (PerkinElmer, Waltham, MA, USA), as previously reported.20 (link) Mice were euthanized on day 35 in accordance with institutional guidelines. Bioluminescence signal intensity representative of tumor sizes was quantified by Living Image 3.1 (PerkinElmer).
To determine the ability of SP and NSP cells to infiltrate the mouse bone marrow (BM), mice (same as above) were injected via the lateral tail vein with 0.2 × 106 sorted SP or NSP cells. Tumor engraftment was monitored using bioluminescence for 3 weeks. Mice were then euthanized and bone marrow cells were flushed with PBS from femora and tibiae using a 25-gauge needle. The percentage of GFP-positive cells was determined by flow cytometry.
Wen J., Tao W., Kuiatse I., Lin P., Feng Y., Jones R.J., Orlowski R.Z, & Zu Y. (2014). Dynamic balance of multiple myeloma clonogenic side population cell percentages controlled by environmental conditions. International journal of cancer. Journal international du cancer, 136(5), 991-1002.
+ Open protocol
+ Expand
5

Evaluating DPP4 Activity in Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols

Example 4

For evaluation of DPP4 enzymatic activity, mice were bled at the time points indicated and plasma samples were collected after centrifugation of blood. For measurements of DPP4 activity in tumor homogenates, tumors growing in mice were dissected, weighted and homogenized in PBS supplemented with protease inhibitor cocktail (Roche). Soluble extracts were collected after centrifugation of tumor homogenates. DPP4 activity in peritoneal cavity was measured by collecting peritoneal washes in 1.5 ml of PBS. DPP4 activity was measured using the DPPIV-Glo™ Protease assay (Promega). To evaluate DPP4 activity in vivo, FVB-Tg(CAG-luc) mice were fed with control and sitagliptin chow 24 hours prior to intraperitoneal injection of 10 mM Gly-Pro-aminoluciferin (Promega). Bioluminescence images were acquired with a XENOGEN (IVIS system, Perkin Elmer), 5 min after injection.

US11000521B2. Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy (2021-05-11). INSTITUT PASTEUR [FR], INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) [FR]. Inventors: Rosa Barreira Da Silva [US], Matthew Albert [FR].
+ Open protocol
+ Expand
6

Adoptive T-cell transfer in NSG mice

Check if the same lab product or an alternative is used in the 5 most similar protocols
All animal experiments were done after approval by the NCI ACUC to follow ethical guidelines. NSG mice were obtained from the NCI repository. We injected subdermally 200 μl per mouse of a 1:1 mixture of PBS:Matrigel (Corning, Corning NY) containing 2×107 MEC1-002 or MEC1-001-Siglec6TG cells stably expressing luciferase. Seven days later 5×106 effector T cells were injected i.v. in 200 μl of PBS. Luminescence was read 15 minutes after i.p. injection of 200 μl of luciferase (15mg/ml) in a Xenogen IVIS system (Perkin Elmer, Hopkinton, MA). Randomization and blinding was performed as follows: transduction of T-cells was performed by a technician and all in vivo procedures and analysis was performed by the investigator without knowledge of the specific group conditions.
Kovalovsky D., Yoon J.H., Cyr M.G., Simon S., Voynova E., Rader C., Wiestner A., Alejo J., Pittaluga S, & Gress R.E. (2021). Siglec-6 is a Target for Chimeric Antigen Receptor T-cell Treatment of Chronic Lymphocytic Leukemia. Leukemia, 35(9), 2581-2591.
+ Open protocol
+ Expand
7

Ovarian Tumor Induction in Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols
All animal work was done in accordance with a protocol approved by the Institutional Animal Care and Use Committee (IACUC) at the Medical College of Wisconsin. Female C57BL/6J mice were obtained from the Jackson Laboratory. Animals were cared for according to IACUC guidelines. All animals were 6 to 8 weeks of age at the time of injection. shRNA control and shRNA furin ID8 cells (1× 106 cells/animal) were prepared in Hanks’ balanced salt solution (Gibco, Carlsbad, CA) and injected into the ovarian bursa (10 mice/group). The mice were imaged once weekly for a bioluminescence signal, using a Xenogen IVIS system (PerkinElmer). At the time of necropsy, the weight, number, and distribution of tumors were recorded.
Chen C., Gupta P., Parashar D., Nair G.G., George J., Geethadevi A., Wang W., Tsaih S.W., Bradley W., Ramchandran R., Rader J.S., Chaluvally-Raghavan P, & Pradeep S. (2020). ERBB3-induced furin promotes the progression and metastasis of ovarian cancer via the IGF1R/STAT3 signaling axis. Oncogene, 39(14), 2921-2933.
+ Open protocol
+ Expand
8

Multiple Myeloma Tumor Xenograft Model

Check if the same lab product or an alternative is used in the 5 most similar protocols
Six week old male NSG mice (Jackson Laboratories, Bar Harbor, ME, USA) were housed in accordance with the Institutional Animal Care and Use Committee (IACUC) (#LUM-001). Each mouse was injected subcutaneously on day 0 with 100 µL of 1.5 × 106 MM1S-luciferase positive cells in sterile serum-free medium. On the next day, 1 × 107 CAR-T cells in serum-free medium were injected intravenously. Imaging was done after luciferin injection using Xenogen Ivis System (Perkin Elmer, Waltham, MA, USA). Quantification was done by measuring bioluminescence (BLI) in photons/sec signals. The Kaplan–Meier survival curve was plotted with GraphPad Prism software using mouse survival data.
Golubovskaya V., Zhou H., Li F., Berahovich R., Sun J., Valentine M., Xu S., Harto H., Sienkiewicz J., Huang Y, & Wu L. (2021). Novel CS1 CAR-T Cells and Bispecific CS1-BCMA CAR-T Cells Effectively Target Multiple Myeloma. Biomedicines, 9(10), 1422.
+ Open protocol
+ Expand
9

Generation of Orthotopic MB-G3 Mouse Models

Cited 4 times
Check if the same lab product or an alternative is used in the 5 most similar protocols
To develop EP-based MBG3 models, in utero EP was performed.37 (link) Only the animals showing luciferase signal by P7 were selected for further analysis. Tumor growth was measured every 1–2 week by bioluminescence imaging of luciferase activity using a Xenogen IVIS system (PerkinElmer, Waltham, MA, USA).41 (link) Orthotopic MBG3 mouse models were generated by cranial implants of purified GNPs from [Trp53−/−; Cdkn2c−/−], [Trp53Fl/-; Atoh1-CreER], [Trp53Fl/-; Prom1-CreER] and [Trp53Fl/-] P6–7 pups, infected with retroviruses carrying Myc and red fluorescent protein according to the previous study.16 (link) No specific randomization or blinding was performed. Tumor cell purification and genomic DNA and total RNA extraction for genotyping and Affymetrix microarray analysis were described previously.16 (link) For detection of non-recombined and recombined alleles of Trp53 in Atoh1ER-MYC and Prom1ER-MYC MBs, 1F/1R (370 bp) and 1F/10R (612 bp) primer sets were used, respectively.42 (link) For internal control, endogenous Prom1 (563 bp)43 (link) and Ptch1 (220 bp)17 (link) were detected. Comparison of survival curves was performed by calculation of two-tailed P-value using the GraphPad Prism software (GraphPad Software, Inc., La Jolla, CA, USA).
Kawauchi D., Ogg R.J., Liu L., Shih D.J., Finkelstein D., Murphy B.L., Rehg J.E., Korshunov A., Calabrese C., Zindy F., Phoenix T., Kawaguchi Y., Gronych J., Gilbertson R.J., Lichter P., Gajjar A., Kool M., Northcott P.A., Pfister S.M, & Roussel M.F. (2017). Novel MYC-driven medulloblastoma models from multiple embryonic cerebellar cells. Oncogene, 36(37), 5231-5242.
+ Open protocol
+ Expand
10

Measuring DPP4 Activity in Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols

Example 4

For evaluation of DPP4 enzymatic activity, mice were bled at the time points indicated and plasma samples were collected after centrifugation of blood. For measurements of DPP4 activity in tumor homogenates, tumors growing in mice were dissected, weighted and homogenized in PBS supplemented with protease inhibitor cocktail (Roche). Soluble extracts were collected after centrifugation of tumor homogenates. DPP4 activity in peritoneal cavity was measured by collecting peritoneal washes in 1.5 ml of PBS. DPP4 activity was measured using the DPPIV-Glo™ Protease assay (Promega). To evaluate DPP4 activity in vivo, FVB-Tg(CAG-luc) mice were fed with control and sitagliptin chow 24 hours prior to intraperitoneal injection of 10 mM Gly-Pro-aminoluciferin (Promega). Bioluminescence images were acquired with a XENOGEN (IVIS system, Perkin Elmer), 5 min after injection.

US11229645B2. Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy (2022-01-25). INSTITUT PASTEUR [FR], INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) [FR]. Inventors: Rosa Barreira Da Silva [US], Matthew Albert [FR].
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!